ACADIA Pharmaceuticals Inc.
ACAD
Classificação em ações
#4430
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Preço da ação
$20.42
Última sincronização: 2026-10-20
Valor de mercado
$3.52B
Variação (1 dia)
3.13%
Variação (1 ano)
-3.99%
País
US
Negociar ACADIA Pharmaceuticals Inc. (ACAD)
Categoria
Healthcare
Receita da ACADIA Pharmaceuticals Inc. (ACAD)
Receita em Jun 2026 TTM: $1.14B
De acordo com os últimos relatórios financeiros da ACADIA Pharmaceuticals Inc., a receita atual da empresa (TTM) é $1.14B. Em 2023, a empresa obteve uma receita de $726.44M um aumento em relação a a receita do ano 2022, que foi de $517.24M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da ACADIA Pharmaceuticals Inc. de 2000 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $1.14B | 18.88% |
| 2024 | $957.80M | 31.85% |
| 2023 | $726.44M | 40.45% |
| 2022 | $517.24M | 6.83% |
| 2021 | $484.15M | 9.60% |
| 2020 | $441.76M | 30.28% |
| 2019 | $339.08M | 51.50% |
| 2018 | $223.81M | 79.19% |
| 2017 | $124.90M | 620.68% |
| 2016 | $17.33M | 28,311.48% |
| 2015 | $61.00K | -49.17% |
| 2014 | $120.00K | -89.52% |
| 2013 | $1.15M | -76.67% |
| 2012 | $4.91M | 137.40% |
| 2011 | $2.07M | -95.09% |
| 2010 | $42.14M | 558.46% |
| 2009 | $6.40M | 302.45% |
| 2008 | $1.59M | -78.95% |
| 2007 | $7.56M | -7.11% |
| 2006 | $8.13M | -25.77% |
| 2005 | $10.96M | 137.96% |
| 2004 | $4.60M | -37.60% |
| 2003 | $7.38M | 17.57% |
| 2002 | $6.28M | 68.97% |
| 2001 | $3.71M | -13.87% |
| 2000 | $4.31M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $12.62B | 1,008.71% |
US
|
|
| $2.23B | 95.67% |
US
|
|
| $15.74B | 1,282.73% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 428.81% |
NL
|
